SCHEMBL21678773

SCHEMBL21678773

COC(=O)/C=C/C(=O)OCc1ccccc1O

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ AKR1B1 P15121 5/20 0.47
▸ AKR1B10 O60218 4/20 0.47
▸ HCAR2 Q8TDS4 2/20 0.46
▸ IDO1 P14902 2/20 0.44
▸ CA12 O43570 3/20 0.44
▸ CA7 P43166 3/20 0.44
▸ CA9 Q16790 3/20 0.44
▸ CA14 Q9ULX7 3/20 0.44
▸ CA1 P00915 1/20 0.44
▸ CA2 P00918 1/20 0.44
▸ TYR P14679 1/20 0.44
▸ MAPT P10636 3/20 0.43
▸ ALDH1A1 P00352 2/20 0.43
▸ KDM4E B2RXH2 1/20 0.43
▸ MEN1 O00255 1/20 0.43
▸ TP53 P04637 1/20 0.43
▸ CYP1A2 P05177 1/20 0.43
▸ CYP2C9 P11712 1/20 0.43
▸ HPGD P15428 1/20 0.43
▸ ALOX15 P16050 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2340792 0.92 HCAR2 (0.53) AKR1B1AKR1B10HCAR2IDO1CA12
SCHEMBL78103 0.92 HCAR2 (0.53) AKR1B1AKR1B10HCAR2IDO1CA12
SCHEMBL21678700 0.87 MAPT (0.52) AKR1B1AKR1B10HCAR2IDO1CA12
SCHEMBL21678780 0.85 HCAR2 (0.65) AKR1B1AKR1B10HCAR2IDO1CA12
SCHEMBL78104 0.85 HCAR2 (0.65) AKR1B1AKR1B10HCAR2IDO1CA12
SCHEMBL5176891 0.85 IDO1 (0.46) AKR1B1AKR1B10HCAR2IDO1CA12
SCHEMBL21678750 0.84 APP (0.50) AKR1B1AKR1B10HCAR2IDO1ALDH1A1
SCHEMBL31003061 0.84 HCAR2 (0.46) HCAR2MAPTALDH1A1KDM4EHPGD
SCHEMBL21678777 0.83 AKR1B1 (0.48) AKR1B1AKR1B10HCAR2IDO1CA12
SCHEMBL28585290 0.83 IDO1 (0.43) AKR1B1AKR1B10IDO1CA12CA7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11866401-B2 Salicyl fumarate derivative and its application in the treatment of Parkinson's disease and other neurodegenerative diseases CHONGQING NEUROPARK BIOSCIENCE CO., LTD. (CN) 2024-01-09 — — US claimed
US-20210179533-A1 SALICYL FUMARATE DERIVATIVE AND ITS APPLICATION IN THE TREATMENT OF PARKINSON'S DISEASE AND OTHER NEURODEGENERATIVE DISEASES CHONGQING NEUROPARK BIOSCIENCE CO., LTD. (CN) 2021-06-17 — — US claimed
EP-3611157-A1 SALICYLIC ACID-BASED FUMARATE DERIVATIVE AND USE IN TREATMENT OF PARKINSON'S DISEASE AND OTHER NEURODEGENERATIVE DISEASES Chongqing Neuropark Bioscience Co., Ltd. (CN) 2020-02-19 — — EP claimed
US-20200048182-A1 A SALICYL FUMARATE DERIVATIVE AND ITS APPLICATION IN THE TREATMENT OF PARKINSON'S DISEASE AND OTHER NEURODEGENERATIVE DISEASES CHONGQING NEUROPARK BIOSCIENCE CO., LTD. (CN) 2020-02-13 — — US claimed
US-11866401-B2 Salicyl fumarate derivative and its application in the treatment of Parkinson's disease and other neurodegenerative diseases CHONGQING NEUROPARK BIOSCIENCE CO., LTD. (CN) 2024-01-09 — — US disclosed
US-20210179533-A1 SALICYL FUMARATE DERIVATIVE AND ITS APPLICATION IN THE TREATMENT OF PARKINSON'S DISEASE AND OTHER NEURODEGENERATIVE DISEASES CHONGQING NEUROPARK BIOSCIENCE CO., LTD. (CN) 2021-06-17 — — US disclosed
EP-3611157-A1 SALICYLIC ACID-BASED FUMARATE DERIVATIVE AND USE IN TREATMENT OF PARKINSON'S DISEASE AND OTHER NEURODEGENERATIVE DISEASES Chongqing Neuropark Bioscience Co., Ltd. (CN) 2020-02-19 — — EP disclosed
US-20200048182-A1 A SALICYL FUMARATE DERIVATIVE AND ITS APPLICATION IN THE TREATMENT OF PARKINSON'S DISEASE AND OTHER NEURODEGENERATIVE DISEASES CHONGQING NEUROPARK BIOSCIENCE CO., LTD. (CN) 2020-02-13 — — US disclosed
CN-106946701-A Salicylic acid-based fumarate derivative and application thereof in treating Parkinson's disease and other neurodegenerative diseases 杨立川 2017-07-14 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210179533-A1 SALICYL FUMARATE DERIVATIVE AND ITS APPLICATION IN THE TREATMENT OF PARKINSON'S DISEASE AND OTHER NEURODEGENERATIVE DISEASES FH, SUCNR1, SDHB AKR1B1 450/4885AKR1B10 532/4885HCAR2 61/4885
US-20200048182-A1 A SALICYL FUMARATE DERIVATIVE AND ITS APPLICATION IN THE TREATMENT OF PARKINSON'S DISEASE AND OTHER NEURODEGENERATIVE DISEASES FH, SUCNR1, SDHB AKR1B1 361/4885AKR1B10 429/4885HCAR2 75/4885
US-11866401-B2 Salicyl fumarate derivative and its application in the treatment of Parkinson's disease and other neurodegenerative diseases FH, SUCNR1, SDHB AKR1B1 483/4885AKR1B10 549/4885HCAR2 88/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback